摘要
支气管哮喘(哮喘)是一种常见的慢性呼吸道疾病,其中5%~10%的患者为重度哮喘。重度哮喘给患者造成了沉重的生理、心理负担,随着不同种类生物制剂的问世,生物制剂治疗重度哮喘初步显示出一定的临床疗效。本文明确了重度哮喘的诊断标准、重度哮喘的分子表型,分析了生物制剂治疗重度哮喘的靶点和生物制剂能否治愈重度哮喘,并分析了长期使用生物制剂的安全性及风险。总之,生物制剂为重度哮喘患者带来了更为精准、更为个体化的治疗选择。
Bronchial asthma(asthma)is a common chronic respiratory disease,with 5%-10%of patients experiencing severe asthma,which poses heavy physiological and psychological burdens on patients.With the emergence of different types of biological agents,certain clinical efficacy has shown in treating severe asthma.This paper clarifies the diagnostic criteria for severe asthma,ascertains the molecular phenotypes of severe asthma,analyzes the targets of biological agents in treating severe asthma,and explores whether biological agents can cure severe asthma.It also analyzes the safety and risks of long-term use of biological agents.In summary,biological agents provide more precise and personalized treatment options for patients with severe asthma.
作者
刘辉国
Liu Huiguo(Department of Respiratory and Critical Care Medicine,National Health Commission Key Laboratory of Pulmonary Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Sciences and Technology,Wuhan 430000,China)
出处
《国际呼吸杂志》
2023年第12期1365-1370,F0002,共7页
International Journal of Respiration
基金
国家自然科学基金(82270104)。
关键词
哮喘
生物制剂
重度哮喘
Asthma
Biological agents
Severe asthma
